Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.

ABSTRACT:

Importance

Patients with type 2 diabetes are at high risk of cardiovascular disease (CVD) in part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol. It is unknown whether adding triglyceride-lowering treatment to statin reduces this risk.

Objective

To determine whether fenofibrate reduces CVD risk in statin-treated patients with type 2 diabetes.

Design, setting, and participants

Posttrial follow-up of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid Study between July 2009 and October 2014; 5 years of follow-up were completed for a total of 9.7 years at general community and academic outpatient research clinics in the United States and Canada. Of the original 5518 ACCORD Lipid Trial participants, 4644 surviving participants

SUBMITTER: Elam MB 

PROVIDER: S-EPMC5470410 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature